ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Dermatology Edition: Top Headlines for Week of October 16, 2023"
Episode Synopsis
In this edition, FDA issues complete response letter for relabotulinumtoxinA; mucocutaneous manifestations may signal COVID-induced inflammatory disease in children and more. Read the full coverage here: FDA issues complete response letter for relabotulinumtoxinA for frown lines, crow's feet Mucocutaneous manifestations may signal COVID-induced inflammatory disease in children FDA approves Zoryve for pediatric psoriasis Colloidal oatmeal, prescription cream comparable in Black children with atopic dermatitis FDA issues complete response letter for lebrikizumab for eczema treatment References: Imam B. Mucocutaneous clinical manifestation of multi-system inflammatory syndrome in children (MIS-C). Presented at: Skin of Color Update; Oct. 6-8, 2023; New York. Lisante TA, et al. J Dermatolog Treat. 2023;doi:10.1080/09546634.2023.2241587. Press Release Press Release Press Release
In God we trust